El-Nasir M A Lalani

Papers ​

  1. Nazia Riaz,Romana Idress, Sadia Habib and El-Nasir Lalani. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer. Front. Oncol., 28 July 2020. Link

  2. Sheerien Rajput ORCID Icon,Khurram Minhas,Iqbal Azam,Usman Shaikh,Azhar Hussain &El-Nasir Lalani.LMP1 expression in bone marrow trephines of patients with multiple myeloma confers a survival advantage.Pages 1991-2001 | Received 22 Nov 2018, Accepted 20 Dec 2018, Published online: 26 Mar 2019. Link

  3. Daniel Barr,Danny Chan,Susan Garfinkel,Zoë Hammatt,Iekuni Ichikawa,Michael Kalichman,El-Nasir Lalani,In Jae Lee,Frederick Leung,Eric Mah,Tony Mayer,Prasit Palittapongarnpim,Theresa Sawicka,Mai Har Sham,Surendra Shastri,Ping Sun,Paul Taylor&Ovid Tzeng.​First meeting in Asia of the Asia Pacific Research Integrity network.Pages 99-106 | Published online: 14 Jan 2020.​ Link​

  4. ​Riaz N, Idrees R, Habib S, Azam I, Lalani E-N. Expression of Androgen Receptor and Cancer Stem Cell Markers (CD44+/CD24- and ALDH+): Prognostic Implications in Invasive Breast Cancer. Translational Oncology. 2018; 11(4): 920-929. Link

  5. Ibrahim S, Siddiqui AA, Siddiqui AR, Ahmed W, Moss PAH and Lalani EM (2016). Sociodemographic factors associated with IgG and IgM seroprevalence for human cytomegalovirus infection in adult populations of Pakistan: a seroprevalence survey.BMC Public Health.2016;16:1112. Link   

  6. Sultana A, Idress R, Naqvi ZA, Azam I, Khan S, Siddiqui AA and Lalani EM (2014). Expression of the androgen receptor, pAkt, and pPTEN in breast cancer and their potential in prognostication. Translational Oncology. 2014;7(3):355-362. Link

  7. Romanska H, Salagierski M, Bruton R, Abel P, Sosnowski M and Lalani EM (2010). Doxazosin induces apoptosis in PTEN–positive androgen-independent PC cells via inhibition of A kt activation. Central European Journal of Urology. 2010; 63(2):91-97. Link

  8. Romanska H, Tiziani S, Howe RC, Günther UL, Gulzar Z and Lalani EM (2009). Nuclear Magnetic Resonance Detects Phosphoinositide 3-Kinase/Akt-Independent Traits Common to Pluripotent Murine Embryonic Stem Cells and Their Malignant Counterparts. Neoplasia. 2009;11(12):1301–1308. Link

  9. Sadej R, Romanska H, Baldwin G, Gkirtzimanaki K, Novitskaya V, Filer AD, Krcova Z, Kusinska R, Ehrmann J, Buckley CD, Kordek R, Potemski P, Eliopoulos AG, Lalani EN and Berditchevski F. CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Mol Cancer Res. 2009;7(6):787-98. Link

  10. El-Sheikh SS, Romanska R, Domin J, Abel P and Lalani EN. Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer--a pilot study. Neoplasia. 2008 Sep; 10(9):949-53. Link

  11. El-Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, Morgan RC, Pollock P, Kockelbergh R, Lalani EN, Dearnaley D, Parmar M and Abel PD (2008). Early hormonal data from a multicentre phase II trial using transdermal patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int. 2008;102(4):442-5. Link 

  12. Rehman KU, Parmar S, Williams R, Dover S and Lalani EN (2008). Research training for oral and maxillofacial surgery. Br J Oral Maxillofac Surg. 2008;46(4):343. Link

  13. Ockrim J, Lalani EN, and Abel P (2006). Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy. Nat Clin Pract Oncol. 2006; 3(10): 552-63. Review. Link

  14. Soeiro I, Mohamedali A, Romanska HM, Lea NC, Child ES, Glassford J, Orr SJ, Roberts C, Naresh KN, Lalani EN, Mann Dj, Watson RJ, Thomas NS and Lam EW (2006).p27Kip1 and p130 cooperate to regulate hematopoietic cell proliferation in vivo. Mol Cell Biol. 2006; 26(16):6170-84. Link

  15. Horne AW, Lalani EN, Margara RA and White JO (2006).The effects of sex steroid hormones and interleukin-1-beta on MUC1 expression in endometrial epithelial cell lines. Reproduction. 2006 Apr;131(4):733-42. Link

  16. Ockrim J,  Lalani EN, Aslam M, Stanfield N and Abel P (2006). Changes in vascular flow after transdermal oestradiol therapy for prostate cancer: a mechanism for cardiovascular toxicity and benefit? BJU International March 2006; 97, 498-504. Link

  17. Baus-Loncar M, Schmid J, Lalani EN, Rosewell I, Goodlad RA, Stamp GW, Blin and N, Kayademir T (2005). Trefoil factor 2 (tff2) deficiency in murine digestive tract influences the immune system. Cell Physiol Biochem. 2005;16(1-3):31-42. Link

  18. Lalani EN, Poulsom R, Stamp G, Fogt F, Thomas P and Nanji AA (2005). Expression of hepatocyte growth factor and its receptor c-met correlates with severity of pathological injury in experimental alcoholic liver disease. Int J Mol Med. 2005 May;15(5):811-7. Link

  19. Ockrim JL, Lalani EN and Abel PD (2005). Re: osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol. 2005 May;173(5):1829. Link

  20. Horne AW, Lalani EN, Margara RA, Ryder TA, Mobberley MA and White JO (2005). The expression pattern of MUC1 glycoforms and other biomarkers of endometrial receptivity in fertile and infertile women. Mol Reprod Dev. 2005 Oct;72(2):216-29. Link

  21. Ockrim JL, Lalani EN, Kakkar AK, Abel PD (2005). Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol. 2005 Aug;174(2):527-33; discussion 532-3. Link

  22. Ockrim JL, Lalani EN, Banks LM, Svensson WE, Blomley MJ, Patel S et al (2004). Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. Urol. 2004 Dec;172(6, Part 1 of 2):2203-2207. Link

  23. Mubashar M, Harrington KJ, Chaudhary KS, Lalani EN, Stamp GW, Peters AM (2004). Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines. Acta Oncol. 2004;43(5):443-52. Link

  24. El-Sheikh SS, Domin J, Abel P, Stamp G and Lalani EN (2004). ErbB2: EGFR ratio is a critical predictor of a mitogenic response to EGF in a prostate cancer model –potential implications for the use of anti-ErbB2 or dual tyrosine kinase inhibitors. Neoplasia. 2004 Nov-Dec; 6(6):846-53. Link

  25. Baus LM, Al-azzeh E, Romanska H, Lalani EN, Stamp G, Blin N and Kayademir T (2004). Transcriptional control of the intestinal trefoil factor (TFF3) via promoter binding sites for the nuclear factor kappaB and C/EBPbeta. Peptides. 2004 May;25(5):849-54. Link

  26. Siu LS, Romanska H, Abel PD, Baus-Loncar M, Kayademir T, Stamp GW, Lalani EN (2004). TFF 2 inhibits apoptosis in breast and colorectal cancer cell lines. Peptides. 2004 May;25(5):855-63. Link

  27. Siu LS, Abel PD, Romanska H, Kayademir T, Blin N, Stamp GWH and Lalani EN (2004). TFF 1 is membrane associated in breast carcinoma cell line MCF-7. Peptides. 2004 May; 25(5): 745-53. Link

  28. Khan A, Abel PD, Chaudhary K, Gulzar Z, Stamp GW and Lalani EN (2003). Inverse Correlation between High-level Expression of Cyclin E and Proliferation Index in Transitional Cell Carcinoma of the Bladder. Mol Pathol. 2003 Dec; 56(6):353-61. Link

  29. Landles C, Chalk S, Steel JH, Rosewell I, Spencer-Dene B, Lalani EN, Parker MG (2003). TRAP220 Is Required At Distinct Embryonic Stages In Placental, Cardiac, and Hepatic Development. Mol Endocrinol. 2003 Dec;17(12):2418-35. Link

  30. El Sheikh SS, Domin J, Abel PD, Tomtitchong P, Stamp GW and Lalani EN (2003). Topographical expression of class IA and class II phosphoinositide 3-kinase enzymes in normal human tissues is consistent with a role in differentiation. BMC Clin Pathol. 2003 Oct 16;3(1):4. Link

  31. Nightingale J, Chaudhary KS, Abel PD, Stubbs AP, Romanska HM, Mitchell SE, Stamp GW and Lalani EN (2003). Ligand activation of the androgen receptor down-regulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells. Neoplasia 2003 July-Aug; 5(4): 347-361. Link

  32. Ochrim JL, Lalani EN, Laniado ME, Carter SS and Abel PD (2003). Transdermal estradiol therapy for advanced prostate cancer–forward to the past. J Urol. 2003 May; 169(5):1735-7. Link

  33. El-Sheikh SS, Domin J, Abel P, Stamp G and Lalani EN (2003). Androgen- Independent prostate cancer: Potential role of androgen and ErbB signal transduction crosstalk.Neoplasia 2003 Mar-Apr; 5(2):99-109. Link

  34. Tadrous PJ, Siegel J, French PM, Shousha S, Lalani EN and Stamp GW (2003). Fluorescence lifetime imaging of unstained tissues: early results in human breast cancer. J Pathol. 2003 Mar;199(3):309-17. Link

Books/ Book Chapters​​

  1. Abel, PD and Lalani EN (Eds) (2003). Prostate Cancer: Scientific and Clinical Aspects – Bridging the Gap. Imperial College Press, London, UK.  ISBN 1-86094-327-6). Contributed 5 out of 38 chapters. 

  2. Lalani EN, Gendler SJ, Peat N, Duhig T and Taylor-Papadimitriou J (1993). Model systems for studying the potential use of the breast associated mucin PEM, in cancer therapy. In AA ed, Monoclonal application in clinical oncology (138-167). Springer Verlag.

  3. Anilkumar TV, Golding M, Sarraf C, Lalani EN and Alison M (1994). Stem cell activation in acetylaminofluorene treated regenerating rat liver: a bile ductular reaction (163-180). In Skoutris GG (Ed), NATO ASI Series. Springer Verlag.

  4. Pignatelli M, Liu D, Nigam AK, Gagliardi G, Stamp GW and Lalani EN (1995). Adhesion molecules in neoplasia: an overview (1-14). In Epenetos AA and Pignatelli M (Eds), Cell adhesion molecules in cancer and inflammation. Harwood Academic Publishers.

  5. Stamp GW, Lalani EN, Hanby AM, Rasbridge S and Pignatelli M (1995). Cell adhesion molecules in mammary carcinoma (15-36). In Epenetos AA and Pignatelli M (Eds) Cell adhesion molecules in cancer and inflammation. Harwoood Academic Publishers.

  6. Williams R, Elia G, Lalani EN and Stamp GW (1995). Neoplastic and hyperplastic alterations in pancreatic ductal epithelium. In Lemoine N and Neoptolemos J (Eds) Diseases of the pancreas. Blackwell Science Ltd, Oxford.

  7. Lalani EN and Stamp GW (1997). Role of the stroma in neoplastic growth and progression (102-124). In Lemoine N and Kirkham N (Eds) Progress in Pathology 3. Churchill Livingstone.

  8. Lalani EN, Stubbs A and Stamp GW (1998). Molecular genetic changes in prostate cancer (113-135). In Lemoine N and Kirkham N (Eds) Progress in Pathology 4. Churchill Livingstone. 

  9. Abel PD and Lalani EN (2003). Prostate Cancer - Some Clinical and Scientific Dilemmas (3-19) (2003). In Abel PD and Lalani EN (Eds) Prostate Cancer – Clinical and Scientific Aspects – Bridging the Gap Part 1. Imperial College Press.

  10. Mitchell SE, Nightigale J, Abel PD and Lalani EN (2003). Cell lines as models of prostate cancer (143-244). In Abel PD and Lalani EN (Eds) Molecular and Cell Biology of Prostate Cancer Part 4, Ch1; Prostate Cancer – Clinical and Scientific Aspects – Bridging the Gap. Imperial College Press.

  11. Laniado ME, Lalani EN, Abel PD (2003). Ion Channels in Prostate Cancer (339-358). In Abel PD and Lalani EN (Eds) Molecular and Cell Biology of Prostate Cancer Part 4, Ch1; Prostate Cancer – Clinical and Scientific Aspects – Bridging the Gap. Imperial College Press.

  12. Mitchell SE, Abel PD, Lalani EN, and Hayward SW (2003). Epithelial-Mesenchymal Interactions in Prostate Cancer (421-454). In Abel PD and Lalani EN (Eds) Molecular and Cell Biology of Prostate Cancer Part 4, Ch 1; Prostate Cancer – Clinical and Scientific Aspects – Bridging the Gap. Imperial College Press.

  13. Chaudhary KS, Abel PD and Lalani EN (2003). Bcl-2 family Proteins and Prostate Cancer Progression: Potential for Therapeutic Interventions (595-618). In Abel PD and Lalani EN (Eds) Molecular and Cell Biology of Prostate Cancer Part 4, Ch1; Prostate Cancer – Clinical and Scientific Aspects – Bridging the Gap. Imperial College Press.